A study led by researchers from MD Anderson Cancer Center shows that radiation or surgical removal of metastatic tumors provides a major survival advantage for lung cancer patients with minimal stage IV disease who have not progressed after frontline chemotherapy.
In April 2025, announcements from the two most influential biomedical agencies in the US, the FDA and the NIH, declared that both will seek to reduce and minimize animal-based testing and experimentation. These declarations sparked joy in some circles, and deep concern in others that was reflected in a 28% fall in the share price of Charles River Labs (NYSE: NYSE:CRL).
